Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Abstract

Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La Roche; BRIM-3 ClinicalTrials.gov number, NCT01006980.).

Keywords

Affiliated Institutions

• Peter MacCallum Cancer Centre AU
• Massachusetts General Hospital US
• University of Tübingen DE
• Nantes Université FR
• The Netherlands Cancer Institute NL
• Royal Marsden Hospital GB
• Hôpital Saint-André FR
• University of Pittsburgh US
• Christian-Albrechts-Universität zu Kiel DE
• University of California, Los Angeles US
• University of Zurich CH
• University of Manchester GB
• Hôpital Saint-Louis FR
• European Institute of Oncology IT
• Institut Gustave Roussy FR
• University Health Network CA
• Angeles Clinic and Research Institute US
• Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" IT
• Vanderbilt University US
• Memorial Sloan Kettering Cancer Center US
• Tumour Institute of Tuscany IT
• Princess Margaret Cancer Centre CA
• Essen University Hospital DE
• La Roche College US

Related Publications